TrialPloS one2022

Investigating the effectiveness of adjuvant therapy for patients with hormone receptor-positive ductal carcinoma in situ.

Chi-Jui Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.